Capsaicin/Diclofenac

Drug Profile

Capsaicin/Diclofenac

Alternative Names: Diclofenac/capsaicin

Latest Information Update: 14 Oct 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Boehringer Ingelheim
  • Class Analgesics; Anti-inflammatories; Catechols; Monounsaturated fatty acids; Non-opioid analgesics; Phenylacetates; Polyunsaturated alkamides; Small molecules
  • Mechanism of Action Cyclooxygenase inhibitors; Substance P inhibitors; TRPV1 receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase III Acute pain

Most Recent Events

  • 21 Jul 2017 Boehringer Ingelheim completes a phase III trial in Acute pain in Russia and Germany (Topical) (NCT02700815)
  • 01 May 2016 Phase-III clinical trials in Acute pain in Germany (Topical) (NCT02700815)
  • 08 Mar 2016 Boehringer Ingelheim plans a phase III trial for Acute pain in Germany, Russia (NCT02700815)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top